Soy β-Conglycinin Peptide Attenuates Obesity and Lipid Abnormalities in Obese Model OLETF Rats

Abstract

IntroductionThe metabolic syndrome is known to increase cardiovascular morbidity and mortality, and central obesity is the key component of its development 1 3 . Although the pathogenesis of metabolic syndrome is complicated, lipid abnormality is proposed as a feature of metabolic syndrome 1 3 . Many studies suggested that plant proteins could be important modulators of the risks associated with this syndrome 4, 5 . For example, several studies have shown that dietary soy protein reduces cholesterol and triglyceride TG levels in animals and humans 4 8 . Moreover soy β-conglycinin βCG , a soybean storage protein, has been reported to exert physiological effects such as promoting lipid lowering effects and preventing obesity in several animal models 9 13 . However, physiological functions of βCG in non-high-fat or non-high-cholesterol diet-fed rodents have not been fully evalutated, and almost all of previous studies have been conducted with diets in which all dietary protein was replaced by βCG even though its es-

Bioactive Peptides: From Basic Research to Clinical Trials and Commercialization

“…For example, in animal models, soy peptides/hydrolysates exert an antidiabetic effect by increasing insulin sensitivity and antiobesity activity by reducing appetite; 63−66 other proposed mechanisms include activation of adenosine monophosphate activated protein kinase (AMPK), 66 increased adiponectin, improved insulin sensitivity, 64 and lipid metabolism. 65,67 Likewise, clinical studies confirm the beneficial effects of soy peptides on obesity and glucose homeostasis. 26,49,52 Lactotripeptides have been extensively studied for their blood pressure lowering activity.…”

“…41,45,84 On the mechanistic front, these peptides activate AMPK, modulate the RAAS pathway, improve insulin sensitivity, and lipid metabolism. 65,66,132 However, clinical and safety studies of other promising bioactive peptides remain elusive. Likewise, there are numerous factors that hinder the clinical exploration and eventual commercialization of bioactive peptides.…”

“…Besides hypertension, metabolic diseases are another front that can benefit from food-derived bioactive peptides. For example, in animal models, soy peptides/hydrolysates exert an antidiabetic effect by increasing insulin sensitivity and antiobesity activity by reducing appetite; − other proposed mechanisms include activation of adenosine monophosphate activated protein kinase (AMPK), increased adiponectin, improved insulin sensitivity, and lipid metabolism. , Likewise, clinical studies confirm the beneficial effects of soy peptides on obesity and glucose homeostasis. ,, Lactotripeptides have been extensively studied for their blood pressure lowering activity. Interestingly, a combination of two lactotripeptides (IPP and VPP) with plant sterols significantly lowered both blood pressure and LDL-cholesterol in hypercholesterolemic patients .…”

Hypolipidemic Effects of Soy Protein and Isoflavones in the Prevention of Non-Alcoholic Fatty Liver Disease- A Review

“…β -conglycinin effectively prevented high-sucrose induced fatty liver through suppression of SREBP-1c and carbohydrate response element-binding protein mRNA [ 59 ], and lowered hepatic triglycerides, serum insulin and leptin concentrations and prevented high-fat induced fatty liver via suppression of liver PPAR γ 2 and/or SREBP-1c protein in mice [ 59 , 70 ]. β -conglycinin and β -conglycinin-derived peptides reduced liver weight and lipid content, and inhibited lipogenic gene expression and enzymatic activity and increased lipolytic enzyme activity in the rat models of NAFLD [ 71 , 72 ]. It was proposed that the hypolipidemic effects of β -conglycinin might be due to increased insulin sensitivity of the liver, down-regulation of hepatic SREBP-1 [ 23 ] and PPARγ2 gene expressions [ 59 ], as well as acceleration of β -oxidation of fatty acids and suppression of FAS and/or increased triglycerides fecal excretion.…”

Association between Equol Production Status and Nonalcoholic Steatohepatitis

“…Otsuka Long-Evans Tokushima fatty (OLETF) rats develop multiple metabolic and hormonal abnormalities that have similar features as obesity in humans [ 17 , 18 ]. OLETF rats spontaneously develop obesity, hypertriglyceridemia, hyperglycemia, hyperinsulinemia, and insulin resistance.…”